Board of Directors

Since 1982, Dr. Samuel Herschkowitz has been a known leader in the area of biotechnology, healthcare devices and pharmaceutical development. Until its merger with Acerus Pharmaceuticals, Dr. Herschkowitz served as the Chairman and Chief Executive Officer as well as a founder of Serenity Pharmaceuticals. During his career, which spans four decades, he was as Strategic Advisor for Amarantus BioSciences, Inc., Dov Pharmaceuticals, Perceptive Systems, Theragenics Corporation, T-Cell Sciences, Oncogene Sciences, Crossover Ventures, and Mira Dx. Between 1998 and 2006 he was a founder and Chief Technical Officer and Chairman of Delcath Systems, Inc. He then served as Interim Chief Operating Officer of Delcath Systems, Inc. from January 4, 2007 to July 1, 2007 before moving on to a fulltime position at Serenity Pharmaceuticals. Earlier in his career, he co-founded Venkol Ventures, a venture capital firm specializing in medical technology investments (1987-2002). Prior to that in 1982, Dr. Herschkowitz was a founder and general partner of Banipal Ventures that specialized in investing in startup healthcare technology and pharmaceuticals. Prior to founding Banipal, Dr. Herschkowitz was a founder of Medtech Associates. Medtech was a consulting company specializing in due diligence investigations on behalf of health care investors. In 1988, he founded Receptor Technologies, Inc. that subsequently was purchased by Senetek, PLC in 1995. From 1995 until 1998 he was a director of Senetek, PLC, a health care company on the London exchange. Dr. Herschkowitz is a Clinical Professor at PANY, an affiliate of New York University Medical Center. He is Board Certified in Psychiatry and Neurology. He received his Medical degree with honors from Downstate Medical Center College of Medicine in 1976.

Mr. Gregory has served as a Director since July 2011. Mr. Gregory is President, Chairman and the controlling shareholder of IsaiX Technologies, a privately held company headquartered in Montreal, with offices in the United States and England. IsaiX Technologies works extensively across a wide variety of industry segments and has ongoing business relationships with more than 100 companies in the pharmaceutical, finance, banking and insurance sectors. IsaiX Technologies provides and implements for its clients human development programs, medical writing and physician scheduling platform services. Mr. Gregory also spearheads charitable endeavours for the children of Canadian soldiers serving overseas. Mr. Gregory has also completed the Institute of Corporate Directors Education Program offered jointly by the Institute of Corporate Directors and the Rotman School of Business of the University of Toronto.

Dr. Cotton is a healthcare executive, venture capital adviser, and angel investor with 20 years experience in the pharmaceutical industry. He spent over 17 years with Gilead Sciences Inc. in Medical Affairs and Commercial roles of increasing responsibility culminating in leadership of the Global Commercial Strategy group, and leadership of the U.S. HIV business unit, with responsibility for over $8B in revenue and $100M of expenses annually. Dr. Cotton has extensive experience in U.S. pharmaceutical product launch and promotion, Key Opinion Leader development, sales leadership and execution, product lifecycle development, U.S. and EU pricing and reimbursement, portfolio strategy, M&A assessment, clinical development, and medical affairs. His therapeutic experience includes anti-virals and anti-infectives, immunology, oncology, cardiovascular, respiratory, and renal disease. Dr. Cotton has worked in the U.S., EU, Global and country level roles. Under Dr. Cotton’s business unit leadership, Gilead launched Genvoya®, Odefsey®, and Descovy® for the treatment of chronic HIV infection, with Genvoya® achieving the fastest launch of any HIV product at that time. Dr. Cotton also launched Truavada® for post exposure prophylaxis, a novel HIV preventative achieving over $1B in revenue in the U.S.

Dr. Cotton graduated in Medicine with a BSc and MB BS from the University of London and practiced internal medicine in the UK prior to joining the pharmaceutical Industry. He has an MBA from Golden State University.